GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

The news followed an investigation by POLITICO's E&E News into climate-friendly inhalers and how drug giants are developing ...

Flovent HFA, GSK’s brand name for its discontinued inhaler, hasn’t been available since December 2023 when, in response to new federal price limits, the company introduced an essentially ...

Dec 9 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder (COPD) in their portfolios, have each committed to becoming ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...